梅克尔细胞癌的诊断与治疗:欧洲共识性跨学科指南——2022年更新
该欧洲共识指南更新了梅克尔细胞癌(MCC)的诊断与治疗推荐。MCC为罕见侵袭性皮肤癌,五分之一以上病例诊断时已有淋巴结受累。指南涵盖诊断、分期、局部与晚期疾病的治疗推荐,包括手术、放疗、前哨淋巴结活检及抗PD-(L)1免疫治疗。
要点
- MCC诊断依靠组织病理学(小细胞神经内分泌外观)和免疫组化(CK20阳性、TTF-1阴性)。
- 局限期MCC一线治疗为手术切除加术后切缘评估,随后辅助放疗;推荐所有无临床可检出淋巴结或远处转移的患者行前哨淋巴结活检。
- 晚期MCC一线系统治疗推荐抗PD-(L)1抗体免疫治疗;化疗可用于免疫治疗失败或不耐受的患者。
核心结论
- MCC为罕见侵袭性皮肤癌,诊断时26%有淋巴结受累、8%有远处转移,五年总生存率48%至63%。
- 病毒阳性MCC较紫外线诱导MCC预后更好;两亚型均存在视网膜母细胞瘤蛋白和p53基因结构与功能改变。
研究设计与样本
- 欧洲共识性跨学科指南2022年更新,基于专家共识制定诊断与治疗推荐。
主要发现
- MCC占所有皮肤恶性肿瘤不足1%,主要见于白人人群,危险因素包括高龄、紫外线暴露、男性、免疫抑制(如AIDS/HIV感染、血液系统恶性肿瘤或实体器官移植)及梅克尔细胞多瘤病毒感染。
- MCC典型表现为红色结节或斑块、生长迅速,最常见于日光暴露部位。
- 现行分期系统为美国癌症联合委员会/国际抗癌联盟第8版。
- 建议基线全身影像学检查以排除区域和远处转移。
关键数值与推荐
- 局限期MCC一线治疗为手术切除加术后切缘评估,随后辅助放疗。
- 推荐所有无临床可检出淋巴结或远处转移的MCC患者行前哨淋巴结活检。
- 微转移性淋巴结受累时,建议单纯辅助放疗,最终联合完全淋巴结清扫。
- 宏观淋巴结受累时,标准治疗为完全淋巴结清扫,可能随后行术后放疗。
- 晚期MCC一线系统治疗应提供抗PD-(L)1抗体免疫治疗;化疗可用于抗PD-(L)1免疫治疗或临床试验失败或不耐受的患者。
临床怎么用
- MCC诊断依靠组织病理学(小细胞神经内分泌外观)和免疫组化(CK20阳性、TTF-1阴性)确认。
- 局限期MCC按推荐行手术切除、术后切缘评估、辅助放疗及前哨淋巴结活检。
- 晚期MCC一线系统治疗提供抗PD-(L)1抗体免疫治疗;化疗用于免疫治疗失败或不耐受者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all cutaneous malignancies. It is found predominantly in white populations and risk factors include advanced age, ultraviolet exposure, male sex, immunosuppression, such as AIDS/HIV infection, haematological malignancies or solid organ transplantation, and Merkel cell polyomavirus infection. MCC is an aggressive tumour with 26% of cases presenting lymph node involvement at diagnosis and 8% with distant metastases. Five-year overall survival rates range between 48% and 63%. Two subsets of MCC have been characterised with distinct molecular pathogenetic pathways: ultraviolet-induced MCC versus virus-positive MCC, which carries a better prognosis. In both subtypes, there are alterations in the retinoblastoma protein and p53 gene structure and function. MCC typically manifests as a red nodule or plaque with fast growth, most commonly on sun exposed areas. Histopathology (small-cell neuroendocrine appearance) and immunohistochemistry (CK20 positivity and TTF-1 negativity) confirm the diagnosis. The current staging systems are the American Joint Committee on Cancer/Union for international Cancer control 8th edition. Baseline whole body imaging is encouraged to rule out regional and distant metastasis. For localised MCC, first-line treatment is surgical excision with postoperative margin assessment followed by adjuvant radiation therapy (RT). Sentinel lymph node biopsy is recommended in all patients with MCC without clinically detectable lymph nodes or distant metastasis. Adjuvant RT alone, eventually combined with complete lymph nodes dissection is proposed in case of micrometastatic nodal involvement. In case of macroscopic nodal involvement, the standard of care is complete lymph nodes dissection potentially followed by post-operative RT. Immunotherapy with anti-PD-(L)1 antibodies should be offered as first-line systemic treatment in advanced MCC. Chemotherapy can be used when patients fail to respond or are intolerant for anti-PD-(L)1 immunotherapy or clinical trials.
引用
- Gauci ML, Aristei C, Becker JC, et al. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022. Eur J Cancer. 2022. PMID: 35732101. doi:10.1016/j.ejca.2022.03.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。